Capital Counsel’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-17,000
| Closed | -$1.73M | – | 54 |
|
|
2023
Q2 | $1.73M | Hold |
17,000
| – | – | 0.1% | 25 |
|
|
2023
Q1 | $1.55M | Hold |
17,000
| – | – | 0.09% | 25 |
|
|
2022
Q4 | $646K | Hold |
17,000
| – | – | 0.04% | 33 |
|
|
2022
Q3 | $427K | Hold |
17,000
| – | – | 0.03% | 39 |
|
|
2022
Q2 | $517K | Hold |
17,000
| – | – | 0.03% | 35 |
|
|
2022
Q1 | $557K | Hold |
17,000
| – | – | 0.03% | 39 |
|
|
2021
Q4 | $448K | Hold |
17,000
| – | – | 0.02% | 43 |
|
|
2021
Q3 | $1.71M | Hold |
17,000
| – | – | 0.08% | 26 |
|
|
2021
Q2 | $2.41M | Hold |
17,000
| – | – | 0.12% | 20 |
|
|
2021
Q1 | $1.7M | Hold |
17,000
| – | – | 0.09% | 27 |
|
|
2020
Q4 | $2.1M | Hold |
17,000
| – | – | 0.12% | 23 |
|
|
2020
Q3 | $1.66M | Hold |
17,000
| – | – | 0.11% | 23 |
|
|
2020
Q2 | $2.65M | Hold |
17,000
| – | – | 0.19% | 19 |
|
|
2020
Q1 | $2.45M | Hold |
17,000
| – | – | 0.2% | 21 |
|
|
2019
Q4 | $3.48M | Sell |
17,000
-20,900
| -55% | -$4.27M | 0.23% | 25 |
|
|
2019
Q3 | $3.04M | Buy |
37,900
+8,900
| +31% | +$715K | 0.21% | 24 |
|
|
2019
Q2 | $2.74M | Sell |
29,000
-1,600
| -5% | -$151K | 0.18% | 25 |
|
|
2019
Q1 | $2.62M | Sell |
30,600
-2,200
| -7% | -$188K | 0.19% | 26 |
|
|
2018
Q4 | $1.84M | Hold |
32,800
| – | – | 0.15% | 26 |
|
|
2018
Q3 | $2.68M | Sell |
32,800
-8,318
| -20% | -$680K | 0.19% | 28 |
|
|
2018
Q2 | $1.44M | Buy |
41,118
+25,118
| +157% | +$878K | 0.11% | 30 |
|
|
2018
Q1 | $328K | Hold |
16,000
| – | – | 0.03% | 49 |
|
|
2017
Q4 | $453K | Hold |
16,000
| – | – | 0.04% | 45 |
|
|
2017
Q3 | $498K | Sell |
16,000
-3,753
| -19% | -$117K | 0.04% | 43 |
|
|
2017
Q2 | $625K | Hold |
19,753
| – | – | 0.06% | 38 |
|
|
2017
Q1 | $447K | Buy |
+19,753
| New | +$447K | 0.04% | 47 |
|